• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Potentially Effective Treatment for Meth Addiction

  Naltrexone-Attenuated Cue-Induced Craving for Methamphetamine (MA) as Compared with Placebo
  Naltrexone-attenuated cue-induced craving for methamphetamine (MA) as compared
with placebo.
Graphic: Courtesy of Dr. Lara Ray

UCLA researchers have found that a drug to treat alcoholism, Naltrexone, may also have promise for the treatment of addiction to methamphetamine. “The results were about as good as you could hope for,” says Lara Ray, PhD, director of the UCLA Addictions Laboratory and a member of the UCLA Brain Research Institute.

The study was the first in the U.S. to evaluate Naltrexone for treating methamphetamine addiction. During a four-day hospital stay, each of the 22 men and eight women in the study were given either Naltrexone or a placebo daily. Ten days later, the subjects were readmitted to the hospital for four more days; those who had taken Naltrexone earlier were given placebos, and vice versa. On the last day of each hospital visit, all participants were given intravenous doses of methamphetamine. Three hours later, the researchers asked how they felt and how much they wanted more of the drug.

The scientists found that Naltrexone significantly reduced the subjects’ craving for methamphetamine and that it made them less aroused by methamphetamine. In addition, participants taking Naltrexone had lower heart rates and pulses when they were presented with their drug paraphernalia than those who were given placebos.

Dr. Ray says the results indicated that Naltrexone reduced the rewarding effects of the drug. Naltrexone was well-tolerated and had very minimal side effects. The researchers found that men and women both were helped, although the positive effect on men was slightly smaller. It made no difference whether or not the participants were given Naltrexone during their first or second hospital stay.

Naltrexone works by blocking opioid receptors in the brain. Dr. Ray says that in previous studies, people undergoing treatment for alcoholism reported getting less of a “high” from drinking when they take Naltrexone. Dr. Ray, whose research team studies the causes of drug and alcohol addiction and possible treatments, plans to examine whether or not Naltrexone would be more effective in combination with other pharmaceuticals and at different doses.

Although the new study is promising, it needs to be backed up by clinical trials, Dr. Ray says. The next step in evaluating Naltrexone’s effectiveness for treating people addicted to methamphetamine is already underway with clinical trials sponsored by the National Institute on Drug Abuse.

“The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: A Double-blind, Placebo-controlled Laboratory Study,” Neuropharmacology, April 15, 2015


Previous
Why Children’s Recovery Times Vary after Traumatic Brain Injury
Next
Protein that Helps Suppress Cancer Fades as We Age


YOU ARE VIEWING

Fall 2015

Fall 2015
E-Brochure
Printable PDF
IN THIS ISSUE
  • We Are the World
  • Camp Leg Power Propels Kids with Cerebral Palsy Forward
  • Portable Finger Probe Measures Liver Function in Potential Donors
  • Stem-cell Therapy Holds Promise for Eliminating HIV Infection
  • REM Sleep Helps Brain Capture Snapshots of Dream Images
  • Germline Cells Shown to be Vulnerable during Pregnancy
  • New Study Opens Window on Mutations in Genetic Architecture of Schizophrenics
  • How Molecular Rules Govern Autoimmune Disorders
  • Predicting Response to Treatment for Obsessive-Compulsive Disorder
  • Why Children’s Recovery Times Vary after Traumatic Brain Injury
  • Potentially Effective Treatment for Meth Addiction
  • Protein that Helps Suppress Cancer Fades as We Age
  • Patient First to Bridge from Experimental Total Artificial Heart to Transplant
  • UCLA Community Based Learning: Bridging the Transition from Youth to Adulthood
  • Get Social
  • The End of Darkness
  • Medicine 2.0
  • White Knight
  • Awards, Honors & Grants
  • In Memoriam
  • Postcard from Malawi
  • In Her Own Words: Lynn L. Huang, MD ’07
  • The Business of Medical Innovation
  • Tribute to a Mentor and Friend
  • Kaleidoscope Ball Highlights Artistic Variety
  • Landmark Gift Paves the Way for Breakthroughs
  • The UCLA Today’s and Tomorrow’s Children’s Fund Names New Awardees
  • Golden Portal Fundraiser Joins Movies, Medicine and Technology
  • Widening the Circle of Giving
  • UCLA Names Landmark New Medical-Education Building Geffen Hall
  • Gifts
  • In Memoriam
  • Good Afternoon, Mrs. Gates
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth